

CHARLES BEISCHEL MD PhD

Eye Center of Charleston
2270 Ashley Crossing Rd #100
Charleston, SC 29414
843-556-2357
Fax: 556-0350

EMPLOYMENT

Private Practice, Comprehensive Ophthalmology

Eye Center of Charleston, Charleston, SC 1998-present

Academic

Clinical Assistant Professor of Ophthalmology, MUSC 1998-present

Staff Physician VA Medical Center, Charleston 1998-2001

EDUCATION

Medical University of South Carolina, Charleston

Chief Resident, Ophthalmology 1997-1998

Residency in Ophthalmology 1995-1998

Internship in Family Medicine 1994-1995

College of Graduate Studies, Pharmacology 1986-1994

Medical Scientist Training Program 1988-1994

M.D. and Ph.D. 1994

Xavier University, Cincinnati, Ohio

B.S., summa cum laude, Chemical Science 1986

Sorbonne, Paris, France

Cours de la Civilisation Francaise, Diplome A 1984-1985

1985

LICENSURE

South Carolina 18663

CERTIFICATION

American Board of Ophthalmology 1999

HONORS/AWARDS

Pierre Gautier-Jenkins Award, Best Teacher at Storm Eye Institute 2004

Program Director's Award, Storm Eye Institute 1997+1998

Resident Best Exemplifying the Qualities the Faculty
and Staff Look for in Their Personal Physician

Chief Resident, Storm Eye Institute 1997-1998

Resident's Research Award, NC/SC Society of Ophthalmology 1997

Alpha Omega Alpha 1993

Letters of Commendation, College of Medicine

Physiology, Pediatrics, Medicine & Surgery 1991-93

Outstanding Immunology Essay Award	1991
Young Investigator's Award	1989
FASEB Summer Conference on the Biology and Chemistry of Vision	
Biophysical Society Travel Award	1989
Medical Scientist Training Program Fellowship, MUSC	1988-1994
Visiting Scientist, Massachusetts Institute of Technology	1987
NIH Mass Spectrometry Facility	
Fredin Memorial Scholarship, Xavier University	1984-1985
Merit Based Full Scholarship for Study at the Sorbonne	
St. Francis Xavier Academic Scholarship, Xavier University	1982-1986
Merit Based Four Year Full Scholarship	

PUBLICATIONS

Papers

- 1) Schluter, SF, CJ Beischel, SA Martin, JJ Marchalonis. 1990 "Sequence Analysis of Homogeneous Peptides of Shark Immunoglobulin Light Chains by Tandem Mass Spectrometry: Correlation with Gene Sequence and Homologies among Variable and Constant Region Peptides of Sharks and Mammals" *Molecular Immunology* 27 (1), 17-23.
- 2) Beischel, CJ, V Mani, R Govindjee, TG Ebrey, DR Knapp, RK Crouch. 1991 "Ring Oxidized Retinals Form Unusual Bacteriorhodopsin Analogue Pigments" *Photochem. Photobiol.* 54(6), 977-983.
- 3) Beischel, CJ, SK Moore, RK Crouch, DR Knapp. 1991 "A Versatile Flash Photolysis Apparatus" *Review of Scientific Instruments* 63(3), 2069-2072.
- 4) Beischel, CJ. 1992 "Studies on Photoaffinity Labeling and Mass Spectrometry of Bacteriorhodopsin" Ph.D. Pharmacology, Dissertation under the direction of Rosalie K. Crouch and Daniel R. Knapp.
- 5) Beischel, CJ, K Gray, ES Hazard, RK Crouch, DR Knapp. 1994 "Evaluation of Photoaffinity Labeled Sites of Bacteriorhodopsin using Molecular Modeling" *Biochem. Molec. Biol. Intll.* 32(5), 933-939.
- 6) Beischel, CJ, DR Knapp, R Govindjee, TG Ebrey, RK Crouch. 1994 "Azidotetrafluorophenyl Retinal Analogue: Synthesis and Bacteriorhodopsin Pigment Formation" *Photochem. Photobiol.* 60(1), 64-68.
- 7) Feng, Y, DR Menick, BM Katz, CJ Beischel, ES Hazard, S Misra, TG Ebrey, RK Crouch. 1994 "Probing of the Retinal Binding Site of Bacteriorhodopsin by Affinity Labeling" *Biochemistry*, 33, 11624-11630.
- 8) Sharpe ED, Day DG, Beischel CJ, Rhodes JS, Stewart JA, Stewart WC. Brimonidine purite 0.15% vs dorzolamide 2% given twice daily to reduce the intraocular pressure in subjects with open-angle glaucoma or ocular hypertension. *Br J Ophthalmol* 2004; 88(7):953-6.
- 9) Day DG, Sharpe ED, Beischel CJ, Jenkins JN, Stewart JA, Stewart WC. Safety and Efficaco of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. *European Journal of Ophthalmology* 2005; 15(3):336-42.

Abstracts & Presentations at National Meetings

- 1) Beischel, CJ, V Mani, DR Knapp, RK Crouch. 1989 "4-Oxoretinal Analogue Pigment of Bacteriorhodopsin" *Biophys. J.* 55, 382a.
- 2) Beischel, CJ, V Mani, DR Knapp, RK Crouch. 1989 "Photoaffinity Labels for Retinal Binding Proteins" FASEB Summer Conference on the Biology and Chemistry of Vision, Saxtons River, Vermont.
- 3) Beischel, CJ, V Mani, TC Williams, RK Crouch. 1989 "Oxidized Retinals as Probes of Retinal Binding Proteins" FASEB Summer Conference on the Biology and Chemistry of Vision, Saxtons River, Vermont.
- 4) Beischel, CJ, V Mani, TC Williams, RK Crouch. 1990 "Oxidized Retinal Based Analogue Pigments of Bacteriorhodopsin" *Biophys J.* 57, 360a.
- 5) Beischel, CJ, V Mani, EA Cohen, DR Knapp, RK Crouch. 1990 "A Novel Photoaffinity Label for Bacteriorhodopsin" *Biophys J.* 57, 365a.
- 6) Crouch, RK, V Mani, C Beischel, P Goletz. 1990 "A Cautionary Note: Retinol in Liposomes Can Auto-oxidize to Form Retinal" *Investigative Ophthalmology & Visual Science* 31/4, 112.
- 7) Feng, Y, BM Katz, JM Chapman, CJ Beischel, DR Menick, RK Crouch. 1994 "Probing of the Retinal-Binding Cavity of Bacteriorhodopsin by Cross-Link" *Biophys J.* 66, A44.
- 8) Auffarth, GU, DJ Apple, CJ Beischel, TA Wesendahl. 1994 "Soemmerring's Ring Formation after Cataract Surgery: An Analysis of 828 Autopsy Eyes" American Society for Cataract and Refractive Surgery, Boston, MA.
- 9) Beischel, CJ, KL Schey, RK Crouch, J Dillon, DR Knapp. 1995 "Mass Spectrometric Analysis of Bovine Lens MP26" *Investigative Ophthalmology & Visual Science* 36(4), S262.
- 10) Beischel, CJ, D LaRoche, KL Schey, RK Crouch. 1998 "Does Phacoemulsification change lens protein structure?" *Investigative Ophthalmology & Visual Science*
- 11) ASCRS/SEI Kiawah Meeting Lecture to Technicians 2003-2006.
- 12) Allergan Speaker's Bureau 2005-2007.

INVESTIGATOR FOR CLINICAL TRIALS

- 1) Inspire Pharmaceuticals, Inc. Protocol 03-105, Phase III, April 2001- January 2002
A Multi-center, double masked, randomized, placebo-controlled, dose ranging study of multiple ocular instillations of INS365 ophthalmic solution vs placebo in subjects with dry eye disease.
- 2) Pharmacia Protocol XALA-0091-157, Phase IV, January 2002 – August 2002
A comparison of study drug with competing drug in patients with elevated intraocular pressure. A twelve week, masked evaluator, Phase IV, multicenter study in the United States.
- 3) Pharmaceutical Research Network, LLC Protocol PRN 01-016, January 2002 – September 2002. The efficacy and safety of dorzolamide 2% or brimonidine-purite 0.15% given twice daily in open angle glaucoma or ocular hypertensive patients.
- 4) Pharmaceutical Research Network, LLC Protocol PRN 01-020, January 2002 – September 2002. A comparison of the efficacy and safety of bimatoprost 0.03% given once every evening vs the timolol/dorzolamide fixed combination given twice daily.

- 5) Allergan Protocol 192371-011, January 2002 – January 2003. A multicenter, double-masked, randomized, vehicle-controlled, parallel-group study of the safety and efficacy of study drug ophthalmic emulsion used twice daily for six months in patients with moderate to severe keratoconjunctivitis sicca.
- 6) Alcon Protocol C-02-049 Phase III, February 2003 – December 2003 Study drug ophthalmic solution 0.15% and brimonidine tartrate ophthalmic solution, 0.2% in patients with open-angle glaucoma or ocular hypertension.
- 7) Pharmaceutical Research Network, LLC Protocol PRN 02-012, July 2002 – April 2003. An economic, efficacy and safety analysis of latanoprost 0.005% versus travoprost 0.004%, bimatoprost 0.03%, and beta blockers in open-angle glaucoma or ocular hypertensive patients.
- 8) Alcon Protocol C-02-52, January 2003 – September 2003. A comparison of study drug ophthalmic suspension, versus ciprofloxacin 0.3% ophthalmic solution, Maxidex ophthalmic suspension and vehicle for treatment of chronic bacterial blepharitis.
- 9) Sucampo Protocol SPI/506OK-0221, Phase II July 2003. A prospective, randomized, phase II, dose ranging, double masked, placebo controlled, parallel-dose, multicenter trial to evaluate the efficacy and safety of FK506 eye drops in subjects with keratoconjunctivitis sicca.
- 10) Allergan Protocol 195263-004-00, July 2003. A multicenter, double-masked, randomized, vehicle-controlled, parallel group study to evaluate the safety and efficacy of testosterone (0.1%, 0.3%, and 0.1%) ophthalmic solution administered twice daily for up to 6 months in patients with meibomian gland dysfunction.